Bioelectronics, the implantation of electrically active devices in the human body, is growing rapidly. However, the metals used for such implants degrade rapidly in the body; can measure only electrical activity, not biochemical; are incompatible with MRI; and can cause toxic byproducts during stimulation. Grapheton is using patented carbon materials to overcome and improve the capabilities of bioelectronic implants.
Location: United States, California, San Diego
Employees: 11-50
Investors 1
| Date | Name | Website |
| - | M1 MedTech | m1medtech.... |
Mentions in press and media 1
| Date | Title | Description |
| 25.10.2021 | US Nuclear : Partner Grapheton Moves to Accelerate Product Development with Help of New CEO | LOS ANGELES, CA, Oct. 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – US Nuclear’s (OTCQB: UCLE) partner Grapheton recently hired a new CEO, Terry Lingren, to accelerate product development by raising funds and allowing founder and CTO Sam ... |